PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Negative EBIT growth while AVXL is at 20.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-22.03%
Negative operating income growth while AVXL is at 20.97%. Joel Greenblatt would press for urgent turnaround measures.
-22.30%
Negative net income growth while AVXL stands at 21.25%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.29%
Negative EPS growth while AVXL is at 22.92%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.29%
Negative diluted EPS growth while AVXL is at 22.92%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Negative 10Y OCF/share CAGR while AVXL stands at 33.38%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
42.89%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
64.68%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-7255.64%
Negative 10Y net income/share CAGR while AVXL is at 50.78%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-121.67%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
22.78%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
5223.15%
10Y equity/share CAGR above 1.5x AVXL's 871.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
855.06%
5Y equity/share CAGR above 1.5x AVXL's 232.21%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-50.27%
Negative 3Y equity/share growth while AVXL is at 1488.12%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Asset growth above 1.5x AVXL's 1.82%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
59.08%
BV/share growth above 1.5x AVXL's 1.60%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
15.66%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
40.35%
SG&A growth well above AVXL's 2.70%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.